Illumina (ILMN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, with virtual attendance available for shareholders.
Shareholders are encouraged to review proxy materials and vote by May 20, 2026.
Voting matters and shareholder proposals
Election of nine directors, with each nominee recommended by the board.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending January 3, 2027.
Advisory vote to approve executive compensation as disclosed in the proxy statement.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election, including Caroline D. Dorsa, Scott Gottlieb, David P. King, Keith A. Meister, Anna Richo, Philip W. Schiller, Susan E. Siegel, Jacob Thaysen, and Scott B. Ullem.
Latest events from Illumina
- Q1 2026 revenue and margins rose, prompting higher guidance and a $1.5B share buyback.ILMN
Q1 20264 May 2026 - Q4 revenue up 5% to $1.16B, non-GAAP EPS up 42%, SomaLogic acquisition completed.ILMN
Q4 202520 Apr 2026 - Proxy seeks approval for director elections, auditor ratification, and executive pay, highlighting strong governance.ILMN
Proxy filing9 Apr 2026 - Sequencing innovation, clinical growth, and end-to-end solutions drive strong outlook.ILMN
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Q2 revenue beat guidance, margins rose, but GRAIL impairments drove a $2.11B net loss.ILMN
Q2 20242 Feb 2026 - Targeting high single-digit revenue growth by 2027 through innovation and margin expansion.ILMN
Strategy Update2 Feb 2026 - MiSeq i100 Series delivers fast, sustainable, and user-friendly sequencing for diverse applications.ILMN
Status Update19 Jan 2026 - Q3 2024 saw strong margins and EPS, robust NovaSeq X adoption, and the GRAIL spin-off.ILMN
Q3 202416 Jan 2026 - Strong clinical and multiomics growth, innovation, and robust financials drive future momentum.ILMN
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026